Business, sports on the docket for Pace expo
Pace Law School will bring together law students and top practicing lawyers in their fields when it hosts its first exposition on intellectual property, sports and entertainment law Sept. 13 on the North Broadway campus in White Plains.
The keynote speaker is attorney James W. Quinn, chairman of the 500-lawyer global litigation practice at Weil Gotshal & Manges L.L.P. in New York and a well-known sports and entertainment litigator.
The program includes a panel discussion on business transactions in sports law. The exposition will run from 8:30 a.m. to noon Tuesday in the moot court room at Pace Law Library. Registration starts at 8 a.m.
Curemark compound ”˜shows promise”™
Rye-based Curemark L.L.C., a biotechnology company developing drug treatments for neurological diseases, said it has had positive results in early testing on mice of a compound to reduce hyperactivity.
Curemark said its CM-182 reduced hyperactivity in mice treated with amphetamines in a mouse-model screening performed by the contract research organization Cerca Insights. The observed results suggested the lowered hyperactivity in the mice was not due to any sedating effect of the compound.
James Szigethy, Curemark director of research and development, said the findings “are consistent with findings of other psychotropic medications utilized to treat hyperactivity, but without the sedating effects.” He said the research reinforces the company”™s previous findings when CM-182 was used to reduce hyperactivity in the mouse model of schizophrenia.
Curemark CEO and founder Joan Fallon said the results “demonstrate that our novel compound indeed shows promise for the treatment of hyperactivity without sedation,” a major effect of multiple drug treatments for hyperactivity that alters patients”™ quality of life.
Curemark plans to continue its investigative studies on CM-182. The company”™s initial products are based on Fallon”™s breakthrough observations of pediatric patients in her former chiropractic practice in Westchester. She found a common lack of protein digestion in children with autism and attention deficit hyperactivity disorder.
